Premium
Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease.
Author(s) -
Barrow SE,
Stratton PD,
Benjamin N.,
Brassfield T.,
Ritter JM
Publication year - 1991
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1991.tb05625.x
Subject(s) - pravastatin , medicine , platelet activation , endocrinology , thromboxane , platelet , thromboxane a2 , cholesterol , thromboxane b2 , excretion
The effect of pravastatin on low density lipoprotein (LDL) cholesterol and platelet activation was studied in 16 patients with mild hypercholesterolaemia who had two or more additional cardiovascular risk factors. Patients were treated with either pravastatin (20‐40 mg day‐1) or placebo for 1 year. Plasma LDL and urinary excretion of 2,3‐ dinor‐thromboxane B2 (an index of platelet activation in vivo) were determined at 0, 3, 6 and 12 months. There was a significant reduction in LDL at 6 and 12 months (2P less than 0.05) but this was not associated with any significant change in thromboxane metabolite excretion.